JBC Focus on PI3-Kinase with Echelon

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Velling, T.
Right arrow Articles by Gullberg, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Velling, T.
Right arrow Articles by Gullberg, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 36, 25735-25742, September 3, 1999


cDNA Cloning and Chromosomal Localization of Human alpha 11 Integrin
A COLLAGEN-BINDING, I DOMAIN-CONTAINING, beta 1-ASSOCIATED INTEGRIN alpha -CHAIN PRESENT IN MUSCLE TISSUES*

Teet VellingDagger , Marion Kusche-Gullberg§, Thomas Sejersen, and Donald GullbergDagger parallel

From the Dagger  Department of Cell and Molecular Biology, BMC, Box 596, Uppsala University, S-751 24 Uppsala, Sweden, § Department of Medical Biochemistry and Microbiology, BMC, Box 575, Uppsala University, S-751 23 Uppsala, Sweden, and  Department of Cell and Molecular Genetics, Karolinska Institute, CMB, Doktorsringen 2D, 171 77 Stockholm, Sweden

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

We previously identified a novel integrin alpha -chain in human fetal muscle cells (Gullberg, D., Velling, T., Sjöberg, G., and Sejersen, T. (1995) Dev. Dyn. 204, 57-65). We have now isolated the full-length cDNA for this integrin subunit, alpha 11. The open reading frame of the cDNA encodes a precursor of 1188 amino acids. The predicted mature protein of 1166 amino acids contains seven conserved FG-GAP repeats, an I domain with a metal ion-dependent adhesion site motif, a short transmembrane region, and a unique cytoplasmic domain of 24 amino acids containing the sequence GFFRS. alpha 11, like other I domain integrins, lacks a dibasic cleavage site for generation of a heavy chain and a light chain, and it contains three potential divalent cation binding sites in repeats 5-7. The presence of 22 inserted amino acids in the extracellular stalk portion (amino acids 804-826) distinguishes the alpha 11 integrin sequence from other integrin alpha -chains. Amino acid sequence comparisons reveal the highest identity of 42% with the alpha 10 integrin chain. Immunoprecipitation with antibodies to alpha 11 integrin captures a 145-kDa protein distinctly larger than the 140-kDa alpha 2 integrin chain when analyzed by SDS-polyacrylamide gel electrophoresis under nonreducing conditions. Fluorescence in situ hybridization maps the integrin alpha 11 gene to chromosome 15q23, in the vicinity of an identified locus for Bardet-Biedl syndrome. Based on Northern blotting, integrin alpha 11 mRNA levels are high in the adult human uterus and in the heart and intermediate in skeletal muscle and some other tissues tested. During in vitro myogenic differentiation, alpha 11 mRNA and protein are up-regulated. Studies of ligand binding properties show that alpha 11beta 1 binds collagen type I-Sepharose, and cultured muscle cells localize alpha 11beta 1 into focal contacts on collagen type I. Future studies will reveal the importance of alpha 11beta 1 for muscle development and integrity in adult muscle and other tissues.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Integrins are heterodimers composed of noncovalently associated alpha - and beta -chains that connect cells to the extracellular matrix or to other cells (1). In addition to acting as mechanical links between the cytoskeleton and extracellular ligands, integrins are signal-transducing receptors that influence processes such as cell proliferation, cell migration, and cell differentiation (2-4). Integrins can be grouped into subfamilies based on shared beta -chains, shared ligand binding properties, or shared structural features of the alpha -chains. Currently, 17 alpha -chains and 8 beta -chains have been identified (5). Of the subfamilies with shared beta -chains, the beta 1 subfamily has the most members. To date, 11 integrin alpha -chains associated with the beta 1 chain have been identified and characterized, alpha 1-alpha 10 and alpha v (5).

Several integrins bind the sequence RGD in their respective ligands (1). Of those integrins identified thus far, alpha 4-, alpha 5-, alpha 8-, alpha IIb-, and alpha v-chains form heterodimers that mediate RGD-dependent interactions. The ligands containing RGD are generally found in the interstitial type of extracellular matrix. Major non-RGD-dependent ligands include various collagen and laminin isoforms. Although both collagens and laminins contain the RGD sequence in their primary sequences, these RGD sequences are cryptic (6-9) and are not normally accessible to cells in the native proteins, but they may be exposed during growth and reorganization events of the extracellular matrix.

Another subdivision of integrins can be made based on structural similarities of the alpha -chains. A number of integrins contain an extracellular (10, 11) that is homologous to collagen binding present in von Willebrand factor (12). The I domain constitutes an inserted domain of approximately 200 amino acids that is present in eight known integrins (alpha 1, alpha 2, alpha 10, alpha L, alpha M, alpha X, alpha D, and alpha E) (5, 10). Structural analysis of integrin I domains crystallized in the presence of Mg2+ have revealed the presence of a characteristic metal ion-dependent adhesion site motif shown to be critical for ligand binding (13). Integrin alpha -chains containing the I domain are not cleaved into heavy and light chains, although the rat alpha 1 chain possesses a proteolytic cleavage site near the membrane-spanning region (14, 15). For I domain integrins, the principal ligand binding sites are found within the I domain (10). Known ligands for I domains found within the beta 1 integrin subfamily include laminins and collagens (alpha 1beta 1 and alpha 2beta 1 integrins) (16-19), and Echovirus (alpha 2beta 1 integrin) (20).

Structure comparisons have suggested that integrins fold into a so-called seven-bladed beta -propeller structure that forms one globular domain with the ligand binding region on the upper surface (21). The I domain is inserted between blades 2 and 3 in this propeller, and divalent cation binding sites are located on the lower surface in blades 4-7 (22, 23). Studies of beta 2 integrins have revealed that proper folding of the beta 2-chain is dependent on the presence of the alpha L-chain, but that the I domain folds independently of other structural elements in the alpha - and beta -chains (24). In integrin alpha -chains, a less conserved stalk region separates the predicted beta -propeller from the short transmembrane region. This stalk region may possibly be involved in transducing conformational changes between the extracellular and intracellular regions, as well as mediating protein-protein interactions. Although integrins take part in cell signaling events, the cytoplasmic tail is short and lacks enzymatic activity. The sequence GFFKR is conserved in a majority of integrin alpha -subunit cytoplasmic tails and has been shown to be important for calreticulin binding (25).

Cellular interactions with the extracellular matrix during muscle formation and in muscular dystrophy have received increased interest during the past years. In the early 1960s, a mutant was described in Drosophila that was characterized by the detachment of muscles from their attachment points at the time of the first embryonic muscle contraction, causing the embryos to assume a spheroid shape (26). The mapping of the molecular defect in the lethal myospheroid mutant in 1988 to an integrin beta -chain (27) was the first evidence for a role of integrins in maintaining muscle integrity. More recently, refined analysis of Drosophila mutants has indicated distinct roles for integrins in muscle end point attachments and sarcomere structure (28). The Drosophila integrins are all cleaved alpha -chains and share many features with vertebrate integrins such as the ability to cluster into focal contacts (29).

The finding that inactivation of the alpha 7 integrin gene in the mouse (30) and mutations in the human ITGA7 gene (31) both cause muscular dystrophy, affecting mainly muscle attachment points, indicates a striking conservation of integrin function during evolution. Of the 11 members of the beta 1 subfamily, alpha 7 exists as a major integrin alpha -chain (32, 33) associated with the beta 1D integrin chain in the adult skeletal muscle sarcolemma (34). Intriguingly, mutations in the basement membrane protein laminin alpha 2-chain (35-37) cause a more severe disease than that observed for the laminin receptor integrin alpha 7beta 1 (30). This indicates that other receptors for laminins exist in muscle.

We recently identified a novel integrin on cultured human fetal muscle cells (38). In the current study, we describe the cloning and characterization of this novel I domain-containing, beta 1-associated integrin chain, which is expressed in muscle tissues.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

Cell Cultures-- The human fetal myoblast/myotube cultures were derived from clone G6 originating from a thigh muscle of a 73-day-old aborted fetus (Ref. 39; referred to as G6 hereafter). Cultures of G6 and 2.5-year postnatal human satellite XXVI cells, a gift from Dr. Helen Blau (Stanford University, Stanford, CA), were grown as reported previously (39). Human rhabdomyosarcoma cell lines RD (ATCC CCL-136) and A204 (ATCC CRL-7900) were grown in Dulbecco's modified Eagle's medium (Swedish Agricultural University, Uppsala, Sweden) supplemented with 10% fetal calf serum.

RNA Isolation and cDNA Synthesis-- Total RNA from G6 and XXVI myoblasts and (the same cells differentiated for 3 or 7 days) and RD and A204 cell lines was isolated using the RNeasy Midi kit (Qiagen) according to the manufacturer's instructions. Poly(A) RNA was extracted from the total RNA of G6 and XXVI cells using the Dynabeads mRNA Direct kit (DYNAL A.S., Oslo, Norway).

PCR1-based Cloning and Generation of Human alpha 11 Probes-- First-strand cDNA was generated from 1 µg of G6 mRNA using a reverse transcription-PCR kit (Perkin-Elmer). Advantage cDNA Polymerase Mix (CLONTECH) was used in PCR amplifications using two different pairs of primers: 1) 5'-ACGGGAGACGTGTACAAGTG-3' (forward) and 5'-AAAGTGCTGAACCTCCACCC-3' (reverse), and 2) 5'-CACCATCCACCAGGCTATGC-3' (forward) and 5'-TTAGCGTTCCGTTATAAACA-3' (reverse). The PCR conditions were 25 cycles of 94 °C for 4 min (hot start), 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min. Two products, named PCR1 and PCR2, were obtained (Fig. 1), subcloned into the plasmid vector TA (Invitrogen), and sequenced. A single product of 1.4 kb in size, named PCR3 (Fig. 1), was amplified using primers 1 (forward) and 2 (reverse) and human heart Marathon-Ready cDNA (CLONTECH) as a template. Annealing temperatures in the applied touch-down program were as follows: 68 °C, 1 min, 5 cycles; 65 °C, 1 min, 5 cycles; and 60 °C, 1 min, 25 cycles. Other steps were as described above. After the final cycle, the reactions were extended for an additional 7 min at 72 °C, followed by a hold step at 4 °C. To obtain the sequence covering the 5' end, rapid amplification of cDNA ends (RACE) was performed according to the manufacturer's instructions (Marathon cDNA Amplification kit; CLONTECH) using cDNA prepared from G6 mRNA and the gene-specific antisense primer 5'-CTTGGAGAACCTGAAGTTGGAGTTGAC-3'. Amplification was carried out applying the touch-down program (see above). To identify relevant products, 10 µl of each RACE product were resolved on a 1% agarose gel and subjected to Southern blot analysis as described previously (40). PCR2 (see above) was labeled with [alpha -32P]dCTP (Amersham Pharmacia Biotech) using the RedyprimeII DNA labeling system (Amersham Pharmacia Biotech) and used as a hybridization probe. One specific signal was detected. Corresponding cDNA was purified (Gel Extraction kit; Qiagen), cloned into the TA vector, and sequenced (see Fig. 1).

Screening of cDNA Libraries-- A lambda ZAP custom-made G6 cDNA library (Stratagene) was screened with PCR2 (see above) as a probe. The screening procedure (carried out as described in Ref. 40) resulted in two clones representing the 5' noncoding region and the beginning of the coding part of integrin alpha 11 (Fig. 1). To obtain additional sequence, a human uterus 5'-stretch lambda gt11 cDNA library (CLONTECH) was screened with a mixture of PCR1 and PCR2 as probes. The probes were labeled with [alpha -32P]dCTP using Ready-To-Go DNA labeling beads (Amersham Pharmacia Biotech). Three clones (Fig. 1, 1.1-1.3) representing parts of alpha 11 cDNA were obtained. Rescreening of the human uterus 5'-stretch lambda gt11 cDNA library with probe lambda 290 (corresponding to nucleotides 2183-2473 in Fig. 1) yielded three more clones (Fig. 1, 2.1-2.3) covering the rest of alpha 11 cDNA. Positive clones were plaque-purified, and the phage DNA was isolated using the Lambda Midi kit (Qiagen) and then subcloned into the Bluescript SK or pUC19 plasmid vectors before sequencing.

Northern Hybridization-- A filter containing 6 µg of the poly(A) RNA from G6 and XXVI cells and 10 µg of the total RNA from RD and A204 cells and a Human Multiple Tissue Northern blot containing poly(A) RNA from adult human tissues (CLONTECH) were hybridized at 68 °C in ExpressHyb solution (CLONTECH) with probes labeled as described above. The probes used were PCR1, PCR2, cDNA clone 1.3 (Fig. 1), 3RA (a 1.8-kb cDNA specific for human integrin alpha 1 mRNA, a generous gift from E. E. Marcantonio (Columbia University, New York, NY)), a 1.1-kb cDNA clone recognizing human glyceraldchyde-3-phosphate dehydrogenase mRNA, and a 1.8-kb cDNA clone recognizing human beta -actin (both from CLONTECH).

cDNA Sequencing and Sequence Analysis-- All PCR fragments and cDNA clones were sequenced on both strands either manually (29) or using an ABI 310 Genetic Analyzer automatic sequencer. Sequences were analyzed with the aid of the MacVectorTM 6.0, DNA Star, FakturaTMNEW 1.2.0, and Sequence Navigator 1.0.1 software programs. A distance tree of all I domain-containing integrin alpha  subunits was assembled using SEAVIEW and PHYLO_WIN software (41). The percentage similarity between every two members in the I domain integrin subfamily was calculated by the formula I = (1 - D) × 100, where I is identity, and D is distance.

Antibodies-- A polyclonal antiserum (alpha 11 cyt) was produced against the peptide CRREPGLDPTPKVLE from the integrin alpha 11 cytoplasmic domain. Peptide synthesis and conjugation to keyhole limpet hemocyanin, immunization of rabbits, and affinity purification were performed at Innovagen AB (Lund, Sweden). The monoclonal antibody MAB 13 against integrin beta 1 was obtained from S. K. Akiyama (National Institute of Environmental Health Sciences, National Institutes of Health). Monoclonal antibodies to integrin alpha 1 (clone FB12, sold as MAB 1973) and integrin alpha 2 (clone BHA2.1, sold as MAB 1998) were both obtained from Chemicon (Temecula, CA). The monoclonal antibody to vinculin (clone hVIN-1) was from Sigma. Secondary fluorescence antibodies (CY3TM-coupled goat-anti-rabbit IgG and FITC-coupled goat anti-mouse IgG of multiple labeling grade) were from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).

Immunoprecipitation and SDS-PAGE-- G6 and XXVI cells were labeled with [35S]cysteine/methionine and subjected to immunoprecipitation and SDS-PAGE as reported previously (38). The two-step procedure used to dissociate integrin heterodimers was carried out as follows. After incubation of samples with beta 1 antibody and capture with GammaBind G-Sepharose (Amersham Pharmacia Biotech), 100 µl of 1% SDS were added to the washed beads that were then boiled for 5 min. 10 mM Tris-HCl, pH 7.4, 0.15 M NaCl, and 1% Triton X-100 were added to a final volume of 1 ml, and the lysate was incubated with GammaBind G-Sepharose for 1 h. The incubation with GammaBind G was performed to ensure that no reactive beta 1 antibodies remained. After the removal of GammaBind G-Sepharose, alpha 11 integrin antibody was added for an additional 2 h, followed by capture with protein A-Sepharose (Amersham Pharmacia Biotech) and boiling in SDS-PAGE sample buffer.

Chromosomal Localization-- Chromosomal localization of the human integrin alpha 11 was performed by using a combination of the fluorescence in situ hybridization (FISH) technique and 4',6-diamidino-2-phenylindole banding essentially as described previously (42). The 1.4-kb reverse transcription-PCR product PCR3 was used as a hybridization probe.

Surface Iodination and Affinity Chromatography-- Cultured XXVI cells were surface-iodinated as described previously (38). Labeled cells were solubilized in 1 ml of solubilization buffer (10 mM Tris-HCl, pH 7.4, 15 mM NaCl, 1% Triton X-100, 1 mM MgCl2, 1 mM CaCl2, and 1 mM MnCl2) and centrifuged at 14,000 × g for 20 min, and soluble membrane proteins were applied to a collagen type I-Sepharose (bovine collagen type I from Vitrogen (Collagen Corp., Palo Alto, CA) coupled to CNBr-activated Sepharose CL-4B at 3 mg/ml gel as described previously (14)), equilibrated in solubilization buffer. After a 1-h incubation, the column was washed extensively with buffer A (10 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM MnCl2, and 0.1% Triton X-100) and with 10 column volumes of buffer A without NaCl. Bound proteins were eluted with 20 mM EDTA, 10 mM Tris-HCl, pH 7.4, and 0.1% Triton X-100. Peak fractions were pooled and concentrated by immunoprecipitation with beta 1 integrin and alpha 11 integrin antibodies as described under "Immunoprecipitation and SDS-PAGE." Eluted fractions and captured proteins were analyzed on 7.5% SDS-PAGE gels, followed by autoradiography.

Indirect Immunofluorescence-- Cells cultured on coverslips were washed in serum-free medium and fixed for 8 min in acetone at -20 °C. Nonspecific binding sites were blocked by incubating with 10% goat serum diluted in phosphate-buffered saline. In the double immunofluorescene staining protocol, primary antibodies (anti-alpha 11 cyt (rabbit antibody) and anti-vinculin (mouse antibody)) were simultaneously incubated with fixed cells for 1.5 h at +37 °C. Specifically bound antibodies were detected using anti-rabbit Cy3 IgG and anti-mouse FITC IgG. Stained cells were mounted in VectashieldTM mounting medium (Vector Laboratories Inc., Burlingame, CA) and visualized and photographed under a Zeiss light microscope equipped with optics for observing fluorescence.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

cDNA Cloning of a Novel Integrin alpha  Chain-- A number of approaches were used to determine the nature of the integrin chain that we had previously characterized on human fetal G6 muscle cells and named alpha mt (38). Applying PCR with mRNA from fetal muscle cells as a template together with degenerate primers to conserved regions of integrin alpha -subunits (43), we amplified cDNA for alpha 1, alpha 4, alpha 5, alpha 6, and alpha v integrin chains (data not shown), but we failed to amplify the novel integrin. However, while searching through the literature, we came across two integrin sequences obtained in a subtractive hybridization protocol comparing human primary myoblasts with the rhabdomyosarcoma cell line RD (44). After having confirmed that these sequences could be amplified by PCR from human fetal G6 myoblast cDNA, PCR was performed assuming that these sequences were derived from the same transcript. In this manner, a 1.4-kb cDNA fragment with an integrin-like sequence was obtained. Screening of a human fetal myoblast cDNA library and 5' RACE yielded an additional 5' sequence. We determined the mRNA expression pattern in a number of human tissues (see below) and observed a high mRNA expression in the uterus. Screening of a uterus cDNA library resulted in the identification of the complete open reading frame. A schematic illustration of the cloning strategy is shown in Fig. 1.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic organization of PCR fragments and cDNA clones representing different parts of the full-length sequence of the integrin alpha 11 subunit. A, clones 1.1-1.3 and 2.1-2.3 are from the first and the second round of screening, respectively. Fragment 0.0 represents a 5' RACE product as well as a clone obtained from screening of the G6 library. PCR fragments 1-3 and a SacI fragment of clone 1.3, lambda 290, are marked with thick lines. Names and positions of all of the clones on the scheme are shown in tabulated form in B. B, names of the PCR-amplified fragments and cDNA clones shown in A are in the left column, and their positions in the full-length cDNA of integrin alpha 11 are shown in the right column.

cDNA Sequence and Predicted Amino Acid Sequence of alpha 11 Integrin Chain-- By sequence analysis of cDNA clones and 5' RACE products, we obtained a continuous sequence of 3983 nucleotides composed of a 90-nucleotide 5' noncoding sequence, a 3564-nucleotide open reading frame, and a 329-nucleotide 3' noncoding sequence. Translation of the sequence predicts an integrin alpha -chain-like precursor of 1188 amino acids including a 22-amino acid-long signal peptide (Fig. 2; GenBank accession number AF137378). The mature 1166-amino acid-long peptide is larger than any other currently identified integrin alpha -chain (with the closest being alpha E, which is composed of 1160 amino acids (45)). The 1115-amino acid-long predicted extracellular domain contains seven FG-GAP repeats in the amino-terminal end with an inserted I domain between repeats 2 and 3. The I domain consists of 195 amino acids and includes a conserved metal ion-dependent adhesion site motif. In addition to the metal chelating site in the I domain, three additional potential divalent cation binding motifs with the consensus sequence DXD/NXDXXXD are present in repeats 5-7. A total of 20 cysteines are located in the extracellular domain. Of these, 16 are conserved in the most closely related integrin alpha 10- and alpha 1-chains, and they may contribute to intramolecular disulfide bonds. Nonconserved cysteines were found at positions Cys606, Cys806, Cys817, and Cys988. Mapping of cysteines in the suggested beta -propeller structure shows that the first three disulfide bonds are likely to stabilize blades 1 and 2 of the beta -propeller, whereas the remaining bonds are found outside the propeller region, in the stalk region toward the transmembrane domain. 16 potential N-glycosylation sites are present in alpha 11. The transmembrane region (amino acids 1142-1164) is 23 amino acids long and is followed by a cytoplasmic tail of 24 amino acids. The cytoplasmic tail contains the sequence GFFRS instead of the conserved GFFKR sequence found in all other alpha -chains except alpha 8-alpha 10. It will be interesting to determine the importance of this sequence in defining the cytoplasmic domain as well as its possible ability to bind calreticulin and other intracellular components.


View larger version (89K):
[in this window]
[in a new window]
 
Fig. 2.   Nucleotide and deduced amino acid sequence of the human integrin alpha 11 chain. The putative signal peptide is underlined in bold, the I domain is boxed, potential N-linked glycosylation sites are marked with asterisks, cysteines are underlined, potential divalent cation binding motifs are double underlined, and the transmembrane domain is underlined with dashes. A 22-amino acid insert is boxed in bold.

Comparison of Integrin alpha 11-Chain with Other Integrin alpha -Chains-- Alignment of the predicted alpha 11 integrin amino acid sequence with other integrin sequences shows the highest overall identity with alpha 10 (42% identity), alpha 1 (37% identity), and alpha 2 (35% identity), followed by the remaining I domain-containing integrin subunits. Of the non-I domain-containing integrins, alpha 4 and alpha 9 are the most similar to alpha 11. A distance tree shows that alpha 10 and alpha 11 form a separate branch from the most closely related alpha 1 and alpha 2 integrin chains (Fig. 3). The similarity with other integrins is particularly high in the amino-terminal beta -propeller part but is lower in the stalk region. Comparison of alpha 1 integrin with alpha 2 integrin has pointed to the presence of a 38-residue insert in the beta -propeller region of the alpha 1 integrin chain (15). Like the alpha 1 chain, alpha 11 also contains inserted amino acids not present in the other I domain-containing integrin chains. However, in the alpha 11 chain, these are found within the stalk region at amino acids 804-826. The exact border of the predicted insertion varies depending on the alignment method and the parameters chosen, but it is predicted to span at least 22 amino acids. The insert contains two cysteines and shows no significant similarity to other integrin sequences (see Fig. 2). We do not believe that the predicted inserted sequence represents a cloning artifact because it is present in three independently analyzed clones. Other examples of non-I domain inserted sequences are found in the Drosophila alpha PS2 chain, in which developmentally regulated splicing in the ligand binding region modulates ligand affinity (46). In the alpha 7 integrin chain, splicing in the extracellular domain between predicted blades 2 and 3 in the beta -propeller generates the X1 and X2 variants, affecting the binding to laminin-1 in a cell-specific manner (47). In the more closely related alpha 1 integrin chain, the 38 extra amino acids are present in a position that is predicted to be in the beginning of the sixth blade of the seven-bladed propeller. Thus far, there is no evidence that the extra amino acids in either alpha 1 or alpha 11 arise by alternative splicing. In alpha 11, the predicted inserted region is outside the beta -propeller and most likely does not directly affect ligand binding. It is nevertheless interesting to note that by binding to the stalk region of certain integrin alpha -chains, tetraspan proteins can recruit phosphatidylinositol 4-kinase and protein kinase C to integrin complexes (48). Likewise the extracellular membrane-proximal parts of certain integrin alpha -chains have been shown to be involved in Shc-mediated integrin signaling (49).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   A distance tree of the I domain-containing alpha -integrin subfamily members. A tree was assembled using ClustalW multiple alignment, based on the SEAVIEW and PHYLOWIN software. A scale at the bottom shows the percentage identity.

Analysis of the sequences identified during screening for genes up-regulated during tadpole regression revealed a partial sequence, which at the time was reported to show the highest similarity to integrin alpha 1 (41% identity) (50). This sequence, when translated (amino acids 1-116), shows 71% identity to human alpha 11 and thus most likely represents the Xenopus orthologue of alpha 11 rather than that of the alpha 1. These data suggest that alpha 11 is well conserved during evolution.

Chromosomal Localization of the Integrin alpha 11 Gene-- A fluorescent cDNA probe was used for in situ hybridization on metaphase chromosome spreads. The analysis shows that the integrin alpha 11 gene (ITGA11) is located on chromosome 15q23 (Fig. 4). The genes for I domain-containing integrins alpha 1 and alpha 2 are both present on chromosome 5 (51, 52), just as the genes for the closely related beta 2 integrin-associated alpha -chains all map to chromosome 16 (53). Interestingly, the alpha 11 gene and the closely related alpha 1 and alpha 2 genes map to different chromosomes. It will be of evolutionary interest to determine the chromosomal localization of the integrin alpha 10 gene. Curiously, a form of Bardet-Biedl syndrome characterized by retinitis pigmentosa, polydactyly, obesity, hypogenitalism, mental retardation, and renal anomalies maps to 15q22-23 (54).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 4.   Chromosome mapping of the ITGA11 gene by FISH. A, the left panel shows the FISH signals on human chromosome 15; the right panel shows the same mitotic figure stained with 4',6-diamino-2-phenylindole to identify human chromosome 15. B, diagram of the FISH mapping result for probe PCR3 based on a detailed analysis of 10 different images. Each dot represents the double FISH signals detected on human chromosome 15.

Expression Pattern of alpha 11 mRNA in Adult Tissues-- Northern blot analysis of mRNA from various adult human tissues shows the highest level of expression of alpha 11 in the adult human uterus. A strong signal is also noted in the heart, whereas intermediate levels of alpha 11 mRNA are present in skeletal muscle, and intermediate to low levels are present in other adult nonmuscle tissues such as the pancreas, kidney, and placenta (Fig. 5; data not shown). For a comparison, the same blot was probed for the closely related alpha 1 integrin mRNA (Fig. 5). A striking difference in the expression levels of alpha 1 and alpha 11 was observed in the smooth muscle-rich uterus, which appears to lack alpha 1. Immunohistochemical analysis and in situ hybridizations will elucidate the detailed distribution of alpha 11 protein and mRNA in muscle and other tissues. Neither alpha 1 (33) nor alpha 2 (55) is present in muscle fibers, and the distribution of alpha 10 in skeletal muscle tissues is not known (5). Hence, no I domain-containing integrin has yet been reported to be expressed in the skeletal muscle sarcolemma. Recently, the gene for alpha 1 integrin was inactivated in mice, resulting in mice with an apparently normal phenotype (56). More careful analysis revealed a phenotype characterized by a hypocellular skin (57) and aberrant regulation of collagen synthesis (58). It will be interesting to compare sites of overlapping expression among alpha 1, alpha 2, and alpha 10 integrins and to use reagents to alpha 10 and alpha 11 to examine possible functional compensatory mechanisms in alpha 1 integrin-deficient mice.


View larger version (108K):
[in this window]
[in a new window]
 
Fig. 5.   Expression of integrin alpha 11 and alpha 1 subunit mRNAs in adult human tissues. Integrin alpha 11 mRNA and integrin alpha 1 mRNA were analyzed on a membrane with RNA from various adult human tissues where mRNA loading was normalized with respect to beta -actin. Probes used for hybridizations are marked on the left. The size standard is marked to the right. Note that the beta -actin probe reacts with 2 kb of beta -/gamma -actin transcripts and the muscle-specific 1.8-kb alpha -actin message.

Biochemical Characterization of alpha 11 Protein-- After the cloning of the full-length alpha 11 integrin cDNA, it was essential to determine whether the predicted amino acid sequence was identical to the novel uncleaved beta 1 integrin-associated alpha -chain that we had previously noted to be up-regulated during in vitro differentiation of human myoblasts (38). To answer this question, we raised antibodies to the cytoplasmic tail of the integrin alpha 11 chain. Immunoprecipitation from the human satellite cells showed that the antibodies precipitated a 145-kDa alpha 11 band associated with a 115-kDa beta 1 band (Fig. 6A) in SDS-PAGE under nonreducing conditions. Under reducing conditions, the alpha 11 band migrated as 155 kDa (see Fig. 6B). From the translated amino acid sequence, a Mr of 133,400 is predicted for the alpha 11 chain. Taking the 16 potential glycosylation sites into account, this fits well with the observed 155-kDa band in SDS-PAGE. Under nonreducing conditions, the 145-kDa band is distinctly larger than alpha 2 (Fig. 6A) and alpha 10 integrin chains that co-migrate as 140-kDa bands, and alpha 11 migrates well below the 180-kDa integrin alpha 1 band. The alpha 2 (59) and alpha 10 (5) integrin chains both contain 10 potential glycosylation sites, whereas alpha 1 contains 26 glycosylation sites (60). The intermediate size of alpha 11 in SDS-PAGE compared with alpha 1 and alpha 2/alpha 10 is thus most likely a result of differential glycosylation.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 6.   Biochemical characterization of integrin alpha 11 chain and up-regulation of corresponding protein and mRNA in myogenic cells. A, alpha 11 associates with the beta 1 integrin chain. Human XXVI muscle cells grown in differentiation medium were metabolically labeled with [35S]cysteine/methionine, and integrins were immunoprecipitated with the indicated antibodies (beta 1, alpha 2, and alpha 11). Evidence for the association of integrin alpha 11 with the beta 1-subunit was obtained by treating proteins precipitated with anti-beta 1 antibodies with SDS, followed by a second precipitation with alpha 11 antibodies (anti-alpha 11 + SDS). Precipitated proteins were resolved on 7.5% SDS-PAGE gels in the absence of reducing agents, followed by fluorography. B, induction of integrin alpha 11 upon myogenic differentiation in vitro. G6 muscle cells were metabolically labeled with [35S]cysteine/methionine when growing in proliferation medium (mb, proliferating myoblasts) and after 7 days in differentiation medium (mt, myotubes). Integrins were precipitated with antibodies to beta 1 and alpha 11, and the precipitates were resolved on 7.5% SDS-PAGE gels both under nonreducing (UNREDUCED) and reducing (REDUCED) conditions. Lanes 1, 3, 5, and 7 are immunoprecipitations with the antibody to integrin beta 1, and lanes 2, 4, 6, and 8 are immunoprecipitations with the antibody to integrin alpha 11. C, up-regulation of integrin alpha 11 mRNA in differentiated myogenic cells. mRNA was extracted from G6 and XXVI cells growing under proliferating (p) or differentiating (d) conditions for 3 days (d3) or 7 days (d7). Total RNA was isolated from RD and A204 cells. Following separation of RNA on agarose gel and transfer to the membrane, the filter was hybridized with probes to alpha 11 integrin (alpha 11) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The size of bands in RNA standard (in kb) is marked to the right.

To show that alpha 11 is associated with the beta 1-subunit, we performed a two-step immunoprecipitation procedure. Integrins were first precipitated with a monoclonal anti-beta 1 integrin antibody, and GammaBind G-captured integrins were then dissociated by boiling in 1% SDS. In the second step, SDS was diluted tenfold, and antibodies to alpha 11 were added. As shown in Fig. 6A, antibodies to alpha 11 immunoprecipitate only the 145-kDa band from the dissociated precipitate initially captured with beta 1 antibodies.

Induction of alpha 11 mRNA and Protein during Myogenic Differentiation in Vitro-- We have previously determined that alpha mt is the major integrin alpha -chain that is up-regulated during myogenic differentiation on human fetal myoblasts in vitro (38). To compare alpha 11 levels in myoblasts and myotubes, immunoprecipitates were analyzed from myoblast cultures in proliferation medium and from parallel cultures allowed to differentiate and form myotubes in differentiation medium for 7 days. Immunoprecipitation with both beta 1 and alpha 11 antibodies showed that alpha 11, like alpha mt, is strongly up-regulated at the protein level in differentiating cultures of human fetal muscle cells and satellite cells (Fig. 6B). To determine whether the up-regulation occurs at the mRNA level or the protein level, we analyzed alpha 11 mRNA from different differentiation stages (day 1, day 3, and day 7) (Fig. 6C). At day 3 in differentiation medium, a strong up-regulation of alpha 11 mRNA was already noted, establishing that the up-regulation of alpha 11 integrin protein occurs as a result of increased transcription or mRNA stability. Based on similar SDS-PAGE migration patterns, similar behavior under reducing conditions, association with the beta 1 integrin chain, and up-regulation during in vitro differentiation of human fetal myoblasts, our data show that alpha 11 integrin is identical with alpha mt.

Analysis of mRNA from the two rhabdomyosarcoma cell lines, RD and A204 (Fig. 6C), did not provide evidence for the presence of alpha 11 in either cell line. Based on the observed up-regulation of alpha 11beta 1 in human fetal muscle cells and the presence of alpha 11 message in adult muscle, we suggest that the alpha 11 integrin might be involved in the early steps of muscle formation and that it may fulfill a stabilizing role in adult muscle tissues. The alpha 7 integrin subunit is a major beta 1-associated integrin chain in muscle, but genetic deletion of alpha 7 leads to a fairly mild muscular dystrophy (30). It remains to be seen whether alpha 11 and alpha 7 integrin chains have overlapping functions in muscle.

Ligand Binding Specificity of alpha 11beta 1 Integrin-- The I domain-containing integrins of the beta 1 integrin subfamily that have been identified thus far all bind collagens (5, 15, 59). For alpha 1 and alpha 2 this binding capacity has been shown to reside within the I domain (17, 18). To determine whether alpha 11beta 1 also binds collagen, we performed collagen type I-Sepharose chromatography of membrane proteins from surface-iodinated XXVI satellite cells. Direct analysis of the EDTA eluate revealed weak bands corresponding to the positions of alpha 1, alpha 2, alpha 11, and beta 1 in parallel immunoprecipitations (Fig. 7a). The EDTA eluate was concentrated by immunoprecipitation with beta 1 and alpha 11 antibodies. As shown in Fig. 7, a prominent alpha 11 band is present in the collagen I-Sepharose eluate. The relatively weak beta 1 band in the proteins captured with alpha 11 antibodies indicates that the alpha 11beta 1 heterodimer partly dissociates in the presence of EDTA.


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 7.   Ligand binding properties of alpha 11beta 1 integrin. a), collagen binding integrins on XXVI cells. XXVI cells were surface-iodinated, and integrins were analyzed by immunoprecipitation and collagen I-Sepharose affinity chromatography. Immunoprecipitation reveals the presence of beta 1 integrins (lane 1) alpha 1beta 1 (lane 2), alpha 11beta 1 (lane 3), and alpha 2beta 1 (lane 4) at the surface of XXVI cells. EDTA-eluted proteins bound to collagen I-Sepharose contain weak bands in the position of alpha 1, alpha 11, alpha 2, and beta 1 integrin chains (lane 5). Immunoprecipitations with beta 1 integrin antibodies (lane 6) and alpha 11 integrin antibodies (lane 7) confirm the presence of alpha 11 and beta 1 in the EDTA eluate. b), alpha 11beta 1 localizes to focal contacts on collagen. Indirect immunofluorescent visualization of vinculin (A and B) and alpha 11 integrin chain (C and D) in human XXVI satellite cells seeded on collagen type I (A and C) and fibronectin (B and D). Note the localization of integrin alpha 11 chain to focal contacts of cells allowed to attach to collagen, and its complete absence on cells seeded on fibronectin. Vinculin is found in focal contacts on both substrates. A and C show the same cell double-stained for both antigens. Scale bar, 20 µm.

To visualize the interaction of alpha 11beta 1 integrin with collagen I in intact cells, myogenic cells expressing alpha 11beta 1 were trypsinized and plated on collagen and fibronectin for 1 h. The ability to form focal contacts was investigated by double immunofluorescence staining for alpha 11-chain and vinculin. As seen in Fig. 7b, alpha 11 localizes to vinculin-positive focal contacts on collagen, but not on fibronectin. Binding studies with alpha 11 I domain expressed as a bacterial glutathione S-transferase-fusion protein also confirmed a specific affinity for collagen I (2). Stable transfections of alpha 11 cDNA into cells with various integrin backgrounds will allow a more detailed study of alpha 11beta 1 interactions with different collagen isoforms and possibly also with laminin isoforms. Combined with in vivo distribution studies of alpha 11beta 1, this is likely to yield valuable information regarding the in vivo ligands for alpha 11beta 1 in different tissues.

    ACKNOWLEDGEMENTS

We are grateful to S. Akiyama for Mab 13 to beta 1 integrin, H. Blau for XXVI satellite cells, SeeDNA Biotech Inc. for help with the chromosomal localization, Maido Remm for help with the distance tree, and E. Marcantonio for integrin alpha 1 cDNA. We acknowledge the technical assistance of P. Jalonen, G. Dombus, A. Wraith, and T. Timmusk and support from P. Ekblom.

    FOOTNOTES

* This work was supported by Medical Research Council Grants 12X-10817 (to D. G.) and 32X-13109 (to T. S.) and by grants from Gustaf V:s fond (to D. G.), Bergvalls stiftelse (to D. G.), and Ronald McDonald Barnfond (to T. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF137378.

parallel To whom correspondence should be addressed. Tel.: 46-18-471-4175; Fax: 46-18-508095; E-mail: Donald.Gullberg@zoofys.uu.se.

2 M. Höök, R. Rich, and R. Owens, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: PCR, polymerase chain reaction; kb, kilobases; RACE, rapid amplification of cDNA ends; SDS-PAGE, SDS-polyacrylamide gel electrophoresis; FISH, fluorescence in situ hybridization.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

1. Hynes, R. O. (1992) Cell 69, 11-25[CrossRef][Medline] [Order article via Infotrieve]
2. Adams, J., and Watt, F. M. (1993) Development 117, 1183-1198[Medline] [Order article via Infotrieve]
3. Sastry, S. K., and Horwitz, A. F. (1996) Dev. Biol. 180, 455-467[CrossRef][Medline] [Order article via Infotrieve]
4. Gullberg, D., Tiger, C.-F., Lohikangas, L., and Velling, T. (1998) Front. Biosci. 3, 1028-1039
5. Camper, L., Hellman, U., and Lundgren-Akerlund, E. (1998) J. Biol. Chem. 273, 20383-20389[Abstract/Free Full Text]
6. Aumailley, M., Gerl, M., Sonnenberg, A., Deutzmann, R., and Timpl, R. (1990) FEBS Lett. 262, 82-86[CrossRef][Medline] [Order article via Infotrieve]
7. Pfaff, M., Aumailley, M., Specks, U., Knolle, J., Zerwes, H. G., and Timpl, R. (1993) Exp. Cell Res. 206, 167-176[CrossRef][Medline] [Order article via Infotrieve]
8. Davis, G. E. (1992) Biochem. Biophys. Res. Commun. 182, 1025-1031[CrossRef][Medline] [Order article via Infotrieve]
9. Goodman, S. L., Aumailley, M., and von der Mark, H. (1991) J. Cell Biol. 113, 931-941[Abstract/Free Full Text]
10. Dickeson, S. K., and Santoro, S. A. (1998) Cell. Mol. Life Sci 54, 556-566 [CrossRef][Medline] [Order article via Infotrieve]
11. Takada, Y., Kamata, T., Irie, A., Puzon-McLaughlin, W., and Zhang, X. P. (1997) Matrix Biol. 16, 143-151[CrossRef][Medline] [Order article via Infotrieve]
12. Colombatti, A., Bonaldo, P., and Doliana, R. (1993) Matrix 13, 297-306[Medline] [Order article via Infotrieve]
13. Lee, J.-O., Rieu, P., Arnaout, M. A., and Liddington, R. C. (1995) Cell 80, 631-635[CrossRef][Medline] [Order article via Infotrieve]
14. Gullberg, D., Turner, D. C., Borg, T. K., Terracio, L., and Rubin, K. (1990) Exp. Cell Res. 190, 254-264[CrossRef][Medline] [Order article via Infotrieve]
15. Ignatius, M. J., Large, T. H., Houde, M., Tawil, J. W., Barton, A., Esch, F., Carbonetto, S., and Reichardt, L. F. (1990) J. Cell Biol. 111, 709-720[Abstract/Free Full Text]
16. Dickeson, S. K., Walsh, J. J., and Santoro, S. A. (1997) J. Biol. Chem. 272, 7661-7668[Abstract/Free Full Text]
17. Calderwood, D. A., Tuckwell, D. S., Eble, J., Kühn, K., and Humphries, M. J. (1997) J. Biol. Chem. 272, 12311-12317[Abstract/Free Full Text]
18. Tuckwell, D., Calderwood, D. A., Green, L. J., and Humphries, M. J. (1995) J. Cell Sci. 108, 1629-1637[Abstract]
19. Tuckwell, D. S., Reid, K. B. M., Barnes, M. J., and Humphries, M. J. (1996) Eur. J. Biochem. 241, 732-739[Medline] [Order article via Infotrieve]
20. King, S. L., Kamata, T., Cunningham, J. A., Emsley, J., Liddington, R. C., Takada, Y., and Bergelson, J. M. (1997) J. Biol. Chem. 272, 28518-28522[Abstract/Free Full Text]
21. Springer, T. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 65-72[Abstract/Free Full Text]
22. Huang, C., and Springer, T. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3162-3167[Abstract/Free Full Text]
23. Oxvig, C., and Springer, T. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 4870-4875[Abstract/Free Full Text]
24. Huang, C., Lu, C., and Springer, T. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3156-3161[Abstract/Free Full Text]
25. Rojiani, M. V., Finlay, B. B., Gray, V., and Dedhar, S. (1991) Biochemistry 30, 9859-9866[CrossRef][Medline] [Order article via Infotrieve]
26. Wright, T. F. (1960) J. Exp. Zool. 143, 77-99[CrossRef][Medline] [Order article via Infotrieve]
27. MacKrell, A. J., Blumberg, B., Haynes, S. R., and Fessler, J. H. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 2633-2637[Abstract/Free Full Text]
28. Bloor, J. A., and Brown, N. H. (1998) Genetics 148, 1127-1142[Abstract/Free Full Text]
29. Gullberg, D., Fessler, L. I., and Fessler, J. H. (1994) Dev. Dyn. 199, 116-128[Medline] [Order article via Infotrieve]
30. Mayer, U., Saher, G., Fassler, R., Bornemann, A., Echtermeyer, F., von der Mark, H., Miosge, N., Poschl, E., and von der Mark, K. (1997) Nat. Genet. 17, 318-323[Medline] [Order article via Infotrieve]
31. Hayashi, Y. K., Chou, F.-L., Engvall, E., Ogawa, M., Matsuda, C., Hirabayashi, S., Yokochi, K., Ziober, B. L., Kramer, R. H., Kaufman, S. J., Ozawa, E., Goto, Y., Nonaka, I., Tsukahara, T., Wang, J.-Z., Hoffman, E. P., and Arahata, K. (1998) Nat. Genet. 19, 94-97[CrossRef][Medline] [Order article via Infotrieve]
32. Song, W. K., Wang, W., Foster, R. F., Bielser, D. A., and Kaufman, S. J. (1992) J. Cell Biol. 117, 643-657[Abstract/Free Full Text]
33. Martin, P. T., Kaufman, S. J., Kramer, R. H., and Sanes, J. R. (1996) Dev. Biol. 174, 125-139[CrossRef][Medline] [Order article via Infotrieve]
34. Belkin, A., Zhidkova, N. I., Balzac, F., Altruda, F., Tomatis, D., Maier, A., Tarone, G., Koteliansky, V. E., and Burridge, K. (1996) J. Cell Biol. 132, 211-226[Abstract/Free Full Text]
35. Miyagoe, Y., Hanaoka, K., Nonaka, I., Hayasaka, M., Nabeshima, Y., Arahata, K., Nabeshima, Y., and Takeda, S. (1997) FEBS Lett. 415, 33-39[CrossRef][Medline] [Order article via Infotrieve]
36. Xu, H., Christmas, P., Wu, X. R., Wewer, U. M., and Engv